Slingshot members are tracking this event:

Incyte to Discontinue Phase 3 study (JANUS 1) of Ruxolitinib Plus Capecitabine

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Incyte Corporation announced its decision to discontinue its Phase 3 trial (JANUS 1) of ruxolitinib in combination with capecitabine.  The decision is based off interim analysis that demonstrated "ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation".  Following these results, the Company has also decided to discontinue other Incyte-sponsored trials of ruxolitinib in solid tumors.  This includes Phase 3 JANUS 2 study in pancreatic cancer, the Phase 2 sub-study in patients with metastatic colorectal cancer and low CRP, the Phase 2 studies in breast and lung cancer and dose finding study of INCB39110 (a selective JAK1 inhibitor).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ruxolitinib, Capecitabine, Phase 3 Study, Janus 1 Trial